Citadel Advisors
KYTX icon

Citadel Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Citadel Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
29,500
-10,500
-26% -$87.5K ﹤0.01% 10865
2025
Q4 		$376K Sell
40,000
-27,700
-41% -$206K ﹤0.01% 9668
2025
Q3 		$406K Buy
67,700
+28,400
+72% +$114K ﹤0.01% 9629
2025
Q2 		$121K Buy
39,300
+37,700
+2,356% +$93.2K ﹤0.01% 11157
2025
Q1 		$3.09K Sell
1,600
-25,600
-94% -$75.6K ﹤0.01% 13986
2024
Q4 		$102K Buy
27,200
+25,800
+1,843% +$124K ﹤0.01% 11458
2024
Q3 		$6.85K Sell
1,400
-4,500
-76% -$34.7K ﹤0.01% 13396
2024
Q2 		$44.3K Buy
5,900
+5,700
+2,850% +$87.1K ﹤0.01% 11898
2024
Q1 		$4.97K Buy
+200
New +$5.58K ﹤0.01% 13778

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Citadel Advisors's KYTX Position: Q1 2026 in Review

Citadel Advisors reduced its Kyverna Therapeutics (KYTX) stake by 79% in Q1 2026, selling an estimated $1.81M and leaving 58,126 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #9303.

Citadel Advisors first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $13M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Citadel Advisors held 58,126 shares of Kyverna Therapeutics worth $502K as of Q1 2026.
  • Citadel Advisors sold 217,320 Kyverna Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Kyverna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9303 holding.
  • Citadel Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Citadel Advisors's Kyverna Therapeutics position peaked at $13M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.